Susquehanna International Group, LLP Imv Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.47 - $0.75 $34,949 - $55,770	-74,361 Reduced 42.73%	99,656 $52,000
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.45 $10,414 - $26,967	-18,598 Reduced 9.66%	174,017 $114,000
Q1 2022 May 16, 2022	SELL	$1.07 - $1.5 $13,778 - $19,315	-12,877 Reduced 6.27%	192,615 $272,000
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.78 $111,055 - $162,031	91,029 Added 79.53%	205,492 $251,000
Q3 2021 Nov 15, 2021	BUY	$1.35 - $2.16 $83,462 - $133,539	61,824 Added 117.45%	114,463 $190,000
Q2 2021 Aug 11, 2021	SELL	$2.12 - $3.24 $29,156 - $44,559	-13,753 Reduced 20.71%	52,639 $115,000
Q1 2021 May 17, 2021	BUY	$2.92 - $4.41 $111,836 - $168,903	38,300 Added 136.34%	66,392 $220,000
Q4 2020 Feb 16, 2021	BUY	$2.9 - $4.4 $81,466 - $123,604	28,092 New	28,092 $87,000
Q1 2020 May 15, 2020	SELL	$1.4 - $4.92 $14,627 - $51,404	-10,448 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.15 - $3.1 $22,463 - $32,388	10,448 New	10,448 $30,000

Ticker IMV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,452,200
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.